Integrity Pact against fake drugs launched by trio of EU trade groups

The European Association of Pharmaceutical Full-line Wholesalers (GIRP) has announced the creation, with the European Generic Medicines Association (EGA) and the Pharmaceutical Group of the European Union, of the Integrity Pact, officially launched in Brussels, Belgium. The Pact is centered on the concept of strengthening cooperation and improving the transparency of operations between all stakeholders in the pharmaceutical supply chain.

Speaking at a conference titled: How Modern Tools Will Enhance Patients' Safety, the GIRP's president, Rene Jenny, stressed that one of the main objectives of the event was "to push ahead with working together with the representatives of our supply chain partners, pharmacists and generic drug manufacturers, in the interest of patient safety."

The Integrity Pact is open to all operators in the pharmaceutical supply chain, with representatives of the research-based drugmakers likely to lend their support to the initiative, according to Mr Jenny. Other stakeholders, including patient organizations and national authorities will also be invited to participate in the Pact's working group.